1.99

0.51% -0.01

Adc Therapeutics Sa (ADCT)

Overview News Price History Option Chain Discussions Forecast

Adc Therapeutics Sa stock is traded at $1.99, with a volume of 45,282. It is down -0.51% in the last 24 hours and down -36.86% over the past month. ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.

Previous Close:

$1.98

Open:

$1.99

24h Volume:

45,282

Relative Volume:

0.13

Market Cap:

$195.31M

Revenue:

$69.56M

Net Income/Loss:

$-240.05M

P/E Ratio:

-0.8767

EPS:

-2.27

Net Cash Flow:

$-121.90M

1W Performance:

-25.66%

1M Performance:

-36.86%

6M Performance:

-47.18%

1Y Performance:

+172.10%

1-Day Range:

$1.96

$2.0287

1-Week Range:

$1.885

$2.70

52-Week Range:

$0.6883

$6.04

Adc Therapeutics Sa Stock (ADCT) Company Profile

Name

Adc Therapeutics Sa

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

41 21 653 02 00

Address

BIOPOLE, EPALINGES

Employee

274

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

ADCT's Discussions on Twitter

Compare ADCT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADCT	1.99	195.31M	69.56M	-240.05M	-121.90M	-2.27
VRTX	446.87	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	741.28	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	590.30	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	249.22	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	103.67	24.49B	3.30B	-501.07M	1.03B	11.54

Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-10-23	Upgrade	JP Morgan	Underweight → Neutral
Apr-24-23	Downgrade	BofA Securities	Neutral → Underperform
Dec-06-22	Initiated	CapitalOne	Overweight
Nov-09-22	Downgrade	BofA Securities	Buy → Neutral
Sep-21-22	Initiated	JP Morgan	Overweight
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-09-21	Initiated	Wolfe Research	Outperform
Aug-17-21	Resumed	Jefferies	Buy
Aug-09-21	Initiated	RBC Capital Mkts	Outperform
Jun-15-21	Initiated	Cantor Fitzgerald	Overweight
Dec-03-20	Initiated	Stifel	Hold
Oct-29-20	Initiated	H.C. Wainwright	Buy
Jun-09-20	Initiated	BofA/Merrill	Buy
Jun-09-20	Initiated	Cowen	Outperform

View All

Adc Therapeutics Sa Stock (ADCT) Latest News

Nov 19, 2024

Short Interest in ADC Therapeutics SA (NYSE:ADCT) Drops By 9.7% - MarketBeat

Nov 19, 2024

Nov 18, 2024

Head to Head Comparison: ADC Therapeutics (NYSE:ADCT) & Astellas Pharma (OTCMKTS:ALPMY) - Defense World

Nov 18, 2024

Nov 16, 2024

Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26% - Simply Wall St

Nov 16, 2024

Nov 15, 2024

ADC Therapeutics SA (NYSE:ADCT) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 11, 2024

ADC Therapeutics : Guggenheim Healthcare Innovation Conference - Marketscreener.com

Nov 11, 2024

Analysts Set ADC Therapeutics SA (NYSE:ADCT) PT at $8.25 - Defense World

Nov 11, 2024

Nov 09, 2024

ADC Therapeutics Third Quarter 2024 Earnings: EPS Misses Expectations - Yahoo Finance

Nov 09, 2024

Nov 08, 2024

ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% UpsideHere's Why - AOL

Nov 08, 2024

ADC Therapeutics SA (NYSE:ADCT) Receives $8.25 Average Price Target from Analysts - MarketBeat

Nov 08, 2024

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update - Marketscreener.com

Nov 08, 2024

ADC Therapeutics (NYSE:ADCT) Now Covered by Analysts at Stephens - MarketBeat

Nov 08, 2024

Stephens & Co. Initiates Coverage of ADC Therapeutics (ADCT) with Overweight Recommendation - MSN

Nov 08, 2024

Nov 07, 2024